In the summer of 2002, Kalorama Information released a major study on non-psychiatric neurotherapeutic drug markets. At almost 500 pages, the resulting report covered a broad range of neurological agents comprehensively and in depth; however, the breadth and authority of the results proved to be more information than some marketers needed. Smaller biopharmaceutical concerns—some of the real drivers of this market—are more focused on individual neurological disorders such as multiple sclerosis, Alzheimer’s disease, or neurological cancers, rather than the broad therapeutic category as a whole.
Therefore, Kalorama is now offering selections from the neurotherapeutics study, covering each of these topics in turn, while at the same time providing selected overall findings in other disease areas to allow for comparison and context. The selections provide the study’s full results in the specific area and the general context and strategic implications from the full study, all at a fraction of the cost.
Among the selections, you’ll find:
I. Executive Summary (15 pages) —Included in this selection is the complete executive summary from the full neurotherapeutics report, providing you with an overview of the entire neurotherapeutics market and top-level numbers on such neurological diseases as peripheral neuropathy, Parkinson’s disease, and Alzheimer’s disease, among others for the top seven world markets. The executive summary outlines the context of the entire neurology market and how oncology therapeutics fit in.
II. Introduction (31 pages) —Selection includes the overview of neurologic cancer, including prevalence estimates.
III. Treatment (11 pages) —This selection reviews current treatment protocols and the agents used in various forms of brain and spinal tumors.
IV. Progress and Promise in Therapeutic Development (62 pages) —Because progress on other neurotherapeutic fronts can have significant impact on oncology, information about all of the developments in neurogenomics and neural implants that the full study covered are included in this selection. Information specific to cancer includes Table 4-4: Active Clinical Trials Involving Neurologic Cancers.
V. World Market Analysis (28 pages, including 10 tables and 4 figures) —Selection provides complete projections and growth rates for neurologic cancer treatment potential in each of the top world markets. Growth rates for other major neurological diseases are included, along with total world numbers for comparison.
VI. Company Profiles (50 pages) —Profiles of the following companies are included:
- Boston Life Sciences, Inc.
- Cephalon, Inc.
- Curis, Inc.
- D-Pharm Ltd.
- Guilford Pharmaceuticals Inc.
- NeoTherapeutics, Inc.
- Neurobiological Technologies, Inc.
- Neurocrine BioSciences, Inc.
- Titan Pharmaceuticals, Inc.
VII. Conclusions and Strategic Implications (9 pages) —This selection represents all of the analyst’s conclusions from the neurotherapeutics study as a whole, spelling out seven main conclusions and what they mean for developers and marketers of neurotherapeutic agents.
VIII. Glossary (8 pages)
IX. Company Directory (8 pages)